RecruitingPhase 2 / Phase 3NCT07277582
Cardiovascular
Long QT Syndrome
Also known as LQTS, Romano-Ward syndrome, congenital long QT, KCNQ1/KCNH2
Long QT Syndrome is a cardiac channelopathy characterised by prolongation of the QT interval on the electrocardiogram, reflecting delayed myocardial repolarisation, which predisposes affected individuals to life-threatening ventricular arrh
ORPHA:768 ↗Gene KCNQ1Gene KCNH2Gene SCN5APrevalence 1 per 2,000–2,500Onset Congenital; symptoms often in childhood to young adulthoodAutosomal dominant (Romano-Ward); autosomal recessive (Jervell and Lange-Nielsen)
15
studies recruiting now
as of 7 Sept 2026
121
studies registered in total
as of 7 Sept 2026
5
countries with a recruiting site
as of 7 Sept 2026
12 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT05473273
Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle.
RecruitingNCT07644715
AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis
RecruitingNCT06887387
Wearable Devices for Patient Monitoring in Long QT Syndrome
RecruitingNCT06546137
National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 15 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Long QT Syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: SADS Foundation Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Long QT Syndrome
Long QT Syndrome is a cardiac channelopathy characterised by prolongation of the QT interval on the electrocardiogram, reflecting delayed myocardial repolarisation, which predisposes affected individuals to life-threatening ventricular arrhythmias, particularly torsades de pointes, syncope, and sudden cardiac death. The three most common genetic subtypes, LQT1 (KCNQ1), LQT2 (KCNH2), and LQT3 (SCN5A), account for approximately 75% of genotype-positive cases and have distinct arrhythmia triggers and pharmacological treatment implications. Jervell and Lange-Nielsen syndrome, the autosomal recessive form involving biallelic KCNQ1 or KCNE1 mutations, additionally causes congenital profound deafness.
Common clinical features
Syncopal episodes, often triggered by exercise or emotionPalpitations and awareness of rapid or irregular heartbeatSeizure-like episodes due to ventricular tachycardiaProlonged QTc interval greater than 450ms (males) or 470ms (females)Sudden cardiac arrest, particularly in young individualsSwimming-triggered events (characteristic of LQT1)Auditory-triggered events (characteristic of LQT2)Nocturnal events (characteristic of LQT3)
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
5 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Eleclazine
Phase 2Ranolazine (Aspruzyo sprinkle)
Phase 2Lumacaftor (Lumacaftor component of orkambi)
Phase 2Ivacaftor (Ivacaftor component of orkambi)
Phase 1Prinaberel
Before you apply
Things trial teams commonly ask about for Long QT Syndrome. Not eligibility rules; those are set by each study.
- Genetic subtype (LQT1, LQT2, LQT3, etc.) determines eligibility for subtype-specific pharmacological trials; confirm your genotype with a cardiac genetics specialist.
- Baseline QTc measurement under controlled conditions (off QT-prolonging medications) is a standard eligibility benchmark; bring a resting 12-lead ECG performed without confounding drugs.
- A full list of current and recent medications is essential; QT-prolonging drugs commonly exclude participation or require washout periods before screening.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).